Clinical Trials Logo

Clinical Trial Summary

This was a multicenter, open, multi-cohort PHASE I study, consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib multi-cohort expansion). The objective of this study was to evaluate safety, tolerability, pharmacokinetic, Pharmacodynamics and biological characteristics, and initial efficacy in advanced malignant tumors.


Clinical Trial Description

Phase I dose escalation phase:This study predicted a total of 8 dose groups, 3, 15, 45, 90, 180,270,360 and 450 ug/kg. Phase Ib expansion phase: This phase is the multi-cohort indication expansion phase. Based on the data obtained in phase I, chose an appropriate dose continue to explore multi-cohort indications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05666635
Study type Interventional
Source Letolab
Contact Jinying Zhou
Phone +8618911370622
Email zhoujinying@letolab.net
Status Not yet recruiting
Phase Phase 1
Start date December 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Active, not recruiting NCT04538625 - Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy Phase 3
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Recruiting NCT06403436 - A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT03061305 - Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Active, not recruiting NCT02568267 - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Phase 2
Terminated NCT05357898 - Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06277804 - A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor Phase 1
Completed NCT03818347 - Hydrogen Gas for Cancer Rehabilitation N/A
Completed NCT05400265 - Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor Phase 1
Recruiting NCT04705818 - Combining Epigenetic And Immune Therapy to Beat Cancer. Phase 2
Completed NCT01269918 - A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain N/A
Suspended NCT03253575 - CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Completed NCT04084951 - Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Active, not recruiting NCT03445858 - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Early Phase 1
Completed NCT03303365 - Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence N/A
Recruiting NCT05752552 - Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours Phase 1
Active, not recruiting NCT05147272 - Study of RP-6306 With Gemcitabine in Advanced Solid Tumors Phase 1
Terminated NCT04892043 - Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Phase 1